VKTX
Viking Therapeutics Inc
Halal Rating :
Last Price
$32.80
Last updated:
Market Cap
-
7D Change
-15.64%
1 Year Change
43.61%
Company Overview
Industries
Exchange
Next Earnings Date
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company's lead product candidates include VK2809, which is in development for the treatment of thyroid hormone receptor beta agonist for various metabolic disorders, and VK2735 for obesity and metabolic disorders. The company is currently in research and development phase without any commercialized products.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Viking Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.